At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Moxidectindrug
Likely dose
Moxidectin 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study of the Pharmacokinetics and Safety of a Single Dose of Moxidectin Per Oral in Subjects Aged 4 to 17 Years With (or at Risk of) Onchocerciasis to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
In Brief
A Phase 1 clinical trial evaluating Moxidectin for Onchocerciasis. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over. The secondary purpose is to evaluate the safety and pharmacokinetics of a single dose of moxidectin in children and adolescents aged 4 to 17 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnchocerciasis
CountriesGhana
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartMar 2021
Primary CompletionMay 2022
Study CompletionSep 2022
TodayJul 2026
First PostedMay 23, 2019
Enrollment StartMar 29, 2021
Primary CompletionMay 30, 2022
Study CompletionSep 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.1 years ago
Interventions
Moxidectindrug
2 mg tablets